Flatten the Bureaucracy Deregulation and COVID-19 Testing

摘要

FDA and CDC deregulations to provide more COVID-19 testing allowed laboratories and test developers to swiftly develop large quantities of tests and innovative ways to test for the virus. This entrepreneurial effort quickly expanded COVID-19 testing capacity to tens of thousands of tests per day and developed tests for at-home use by means of either nasal swabs or saliva samples. By following the development of newly developed tests and increases in testing availability before and after the FDA deregulatory actions, my findings strongly suggest that the deregulation was instrumental in providing urgently needed testing during the ongoing pandemic.